AKOVAZ Drug Patent Profile
✉ Email this page to a colleague
When do Akovaz patents expire, and when can generic versions of Akovaz launch?
Akovaz is a drug marketed by Exela Pharma and is included in one NDA.
The generic ingredient in AKOVAZ is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Akovaz
A generic version of AKOVAZ was approved as ephedrine sulfate by SANDOZ on August 23rd, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AKOVAZ?
- What are the global sales for AKOVAZ?
- What is Average Wholesale Price for AKOVAZ?
Summary for AKOVAZ
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 21 |
Patent Applications: | 551 |
Drug Prices: | Drug price information for AKOVAZ |
What excipients (inactive ingredients) are in AKOVAZ? | AKOVAZ excipients list |
DailyMed Link: | AKOVAZ at DailyMed |
Pharmacology for AKOVAZ
Drug Class | Norepinephrine Releasing Agent alpha-Adrenergic Agonist beta-Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
Physiological Effect | Increased Norepinephrine Activity |
US Patents and Regulatory Information for AKOVAZ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exela Pharma | AKOVAZ | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208289-002 | Aug 2, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Exela Pharma | AKOVAZ | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208289-001 | Apr 29, 2016 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |